Press Releases

Press Releases

Keyword Search

February 19, 2020
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020
SAN CARLOS, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2019 financial results on Tuesday, February 25, 2020 .
More »
February 12, 2020
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
SAN CARLOS, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences: Guggenheim Healthcare Talks |
More »
January 15, 2020
Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel
- Biologics Licensing Application (BLA) submission planned for late 2020 - SAN CARLOS, Calif. , Jan. 15, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company
More »
January 12, 2020
Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog
SAN CARLOS, Calif. , Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company has obtained a license from Novartis to develop and commercialize an
More »
January 12, 2020
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
Iovance Biotherapeutics Will Use TALEN® Technology from Cellectis to Develop Gene-Edited TIL SAN CARLOS, Calif. and NEW YORK , Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and
More »